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Introduction: Hepatitis C virus reinfection occurs universally after liver transplantation with accelerated cirrhosis rates
of up to 30% within 5 years after liver transplantation. Management of hepatitis C virus reinfection is complicated by
drug interactions and pre-treatment. Dual antiviral therapy with pegylated interferon and ribavirin only reaches
sustained virological response rates of approximately 30% after liver transplantation. With the approval of the viral NS3/
4A protease and NS5B ribonucleic acid -dependent ribonucleic acid polymerase inhibitors, combination therapy offers
new therapeutic options resulting in considerably higher sustained virological response rates in the non-transplant
setting. However, silibinin has also shown potent antiviral activity in non-responders to dual therapy.
Case presentation: We report the first case of antiviral therapy with pegylated interferon and ribavirin in combination
with silibinin post-liver transplantation in a 50-year-old Caucasian man with genotype 3 reinfection with prior
non-response.
Silibinin was administered at a dose of 20mg/kg/day intravenously for 2 weeks and continued orally for 47 weeks in
combination with a 48-week pegylated interferon and ribavirin therapy (180μg/week and 800mg/day), which was
started on day 8. Pegylated interferon and ribavirin doses were adapted to 135μg/week and 600mg/day. After 4 weeks
of therapy, the viral load declined 6 log10 and became undetectable in week 6, resulting in a sustained virological
response 24 weeks after the end of therapy.
In general, antiviral therapy was well tolerated. Side effects included pruritus and anaemia leading to erythropoietin
therapy.
Conclusions: Combination therapy with pegylated interferon, ribavirin and silibinin resulted in sustained virological
response 24 weeks after the end of therapy in a patient reinfected with hepatitis C virus genotype 3 who was a prior
non-responder after liver transplantation. Silibinin therapy may offer a new therapeutic option for patients reinfected
with non-genotype 1 hepatitis C virus who have had a liver transplanted and are non-responders.
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Hepatitis C virus (HCV) reinfection occurs universally
after liver transplantation (LT) [1]. Under immunosup-
pression, the time course of recurrent HCV is accele-
rated, with cirrhosis rates of up to 30% within 5 years of
LT [2]. So far, antiviral therapy has been limited to a
combination of pegylated interferon (peg-IFN) and riba-
virin (RBV) with sustained virological response (SVR)
rates of approximately 30% post-LT [3-5]. With the ap-
proval of the viral NS3/4A protease inhibitor (PI) sime-
previr and NS5B ribonucleic acid (RNA)-dependent
RNA polymerase inhibitor (RdRpI) sofosbuvir, combin-
ation therapy offers new therapeutic options resulting in
considerably higher SVR rates of 66% and 75% in
treatment-naïve patients infected with HCV genotype 1
in the non-transplant setting [6,7]. However, the ma-
nagement of HCV reinfection after LT is complicated by
drug interactions, tolerability and pre-treatment [8,9].
Therefore an individual treatment regimen is often re-
quired. However, PI-based triple therapy is limited to pa-
tients infected with HCV genotype 1. To date, very few
data exist on the treatment of recurrent non-genotype 1
HCV-infection after LT.
As silibinin has been shown to be a potent antiviral
agent in prior non-responders to dual therapy [10,11], we
present here the first case of antiviral therapy with peg-
IFN and RBV in combination with silibinin post-LT in a
genotype 3 reinfected patient with prior non-response.
Case presentation
A 50-year-old Caucasian man underwent a liver trans-
plant in 2008 due to hepatocellular carcinoma based onFigure 1 Course of hepatitis C virus-ribonucleic acid (106 IU/mL), alan
blood cells (cells/nL) and platelets (101/nL) during therapy. After 4 we
week 6 resulting in SVR 24. Side effects included pruritus and anaemia, lead
aminotransferase; EOT, end-of-treatment; Hb, haemoglobin; HCV-RNA, hepa
response; Tacr, tacrolimus; w, week; WBC, white blood cells.chronic HCV genotype 3a-associated liver cirrhosis.
HCV was diagnosed in 1996. He was pre-treated with
dual antiviral therapy pre-LT in 1997, resulting in pri-
mary non-response. In 2008, recurrent HCV was de-
tected in liver biopsy. Therefore, he underwent a second
attempt of dual antiviral therapy over 48 weeks, resulting
in a relapse. He was referred to our LT out-patient clinic
in a good state of general health (body mass index 26.2,
180cm, 85kg) with a request for antiviral therapy. HCV-
RNA measured 14×106 IU/mL (COBAS® TaqMan® HCV
test, version 2.0, Roche Diagnostics AG, Rotkreuz,
Switzerland; lower limit of quantification: 25IU/mL;
lower limit of detection: 10IU/mL). His serum transami-
nases were slightly elevated: alanine aminotransferase
103U/L, upper limit of normal (ULN <50IU/L; aspartate
aminotransferase 114U/L, ULN 35IU/L). All other liver
values were within the normal range (alkaline phospha-
tase, gamma-glutamyltransferase, bilirubin, international
normalized ratio and albumin). Haemoglobin, leukocyte
and thrombocyte counts were 16.6mg/dL, 8.6/nL and
118/nL, respectively (Figure 1). Side diagnoses included
hypertension and diabetes mellitus type 2.
As silibinin has shown potent antiviral activity in prior
non-responders to dual therapy, informed consent was
given for a triple combination therapy of silibinin, peg-
IFN and RBV. He was given tacrolimus 1mg twice a day
(BID) and mycophenolate-mofetil 500mg BID for im-
munosuppression as well as co-medication with amlo-
dipine (5mg/day) and pantoprazole (40mg/day); insulin
injections were also continued. Silibinin was adminis-
tered 20mg/kg/day intravenously for 2 weeks and con-
tinued orally 560mg/day for 47 weeks in combinationine aminotransferase (101U/L), haemoglobin (mg/dL), white
eks of therapy, viral load declined 6 log10 and became negative in
ing to the application of erythropoietin. Abbreviations: ALT, alanine
titis C virus-ribonucleic acid; PLT, platelets; SVR, sustained virological
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and 800mg/day started on day 8. Peg-IFN and RBV doses
were adapted to 135μg/week and 600mg/day. After 4
weeks of therapy, the viral load declined 6 log10 and
became undetectable in week 6, resulting in SVR 24. The-
rapy was well tolerated; side effects included dyspnoea,
pruritus and anaemia, leading to the application of 250mg
BID ursodeoxycholic acid and 30μg erythropoietin/week.
Red blood cell, leukocyte and platelet counts, as well as
tacrolimus through levels, were checked once a week.
Discussion
Antiviral therapy of recurrent HCV after LT is an issue
of high interest and the time course of fibrosis progres-
sion is accelerated under immunosuppression [2]. Im-
provements in antiviral therapy are urgently required as
SVR rates for dual therapy in patients who are HCV
positive after LT are low [3,4]. PI and RdRpI-based com-
bination for antiviral therapy in non-LT cohorts leads to
significantly higher SVR rates compared to a dual the-
rapy [6-10]. However, the management of HCV post-LT
is complicated by drug interactions, side effects and pre-
treatment [11,12].
However, PI-based triple therapy is limited to patients
infected with HCV genotype 1. To date, very few data
exist on the therapy of recurrent non-genotype 1 HCV-
infection after LT.
In vitro experiments have shown that HCV replication
is significantly inhibited by silibinin [13]. Silibinin has a
strong anti-oxidative effect [14]. This may improve the re-
sponse to IFN in non-responders to dual therapy since
oxidative stress leads to impaired IFN signalling [15].
However, evidence for beneficial effects in humans has
been equivocal. Therefore, the efficacy and safety of high-
dose intravenous silibinin, followed by a lower dose oral
application in combination with dual antiviral therapy,
were evaluated by Ferenci et al. [16] in 2008 in chronic
HCV genotype 1, 2 and 4 infected former non-responders.
This study showed that silibinin is well tolerated and re-
veals a substantial antiviral effect against HCV in non-
responders [16]. A recent study reported similar results in
the transplant setting for patients reinfected with HCV
genotype 1 [17]. We present here the first case of success-
ful antiviral treatment with silibinin in combination with
peg-IFN and RBV in a patient reinfected with HCV geno-
type 3 after LT with prior non-response to dual therapy.
Treatment with silibinin might result in an IFN-sensitising
effect in IFN non-responders following LT.
Conclusions
Combination therapy of peg-IFN, RBV and silibinin re-
sulted in SVR 24 in a patient who had a liver transplanted,
who was reinfected with HCV genotype 3 and who was
therapy naïve. Combination therapy with silibinin mightbe a useful approach for the therapy of recurrent non-
genotype 1 HCV infection after LT.
Consent
Written informed consent was obtained from the patient
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